Ultragenyx UK

Heme arginate (internal code 199/13191) is a small-molecule therapeutic being developed by Ultragenyx UK Limited for the treatment of porphyria. The program is currently in Phase 2 development with a completed status as of the latest milestone recorded on 24 June 2005. The associated drug entity in the regulatory record is ferumoxytol (brand name FERAHEME), an intravenous iron supplement classified under blood and blood-forming organs therapeutics (ATC B03). Ferumoxytol has achieved regulatory approval in the United States under multiple sponsors including AZURITY and SANDOZ, with FDA application numbers ANDA206604, NDA022180, and NDA219868. In the European Union, an application was withdrawn; the product was previously authorized under MAHs Covis Pharma Europe B.V. and Takeda Pharma A/S with EMA product numbers EMEA/H/C/002215 and EMEA/H/C/005974, with authorization dated 13 April 2015. The mechanism of action for ferumoxytol remains undisclosed in available regulatory documentation. Three clinical trials have been registered (NCT00004397, NCT00004398, NCT00004789), though detailed trial outcomes are not yet disclosed. The program's current development trajectory and future milestones have not been publicly announced.

Porphyrias represent a group of rare metabolic disorders characterized by defects in heme biosynthesis, resulting in accumulation of porphyrin precursors and causing acute neurovisceral attacks, chronic photosensitivity, and significant morbidity. The acute intermittent porphyrias and variegate porphyria present particularly severe clinical challenges with limited therapeutic options beyond supportive care and glucose loading during acute episodes. Current standard-of-care therapies focus on symptom management rather than addressing underlying pathophysiology, creating a substantial unmet medical need for disease-modifying treatments.

The competitive landscape for porphyria treatment is dominated by erythropoietin receptor agonists (OMONTYS, EPORATIO, MIRCERA, ARANESP, NEORECORMON, DYNEPO, RETACRIT) and emerging hypoxia-inducible factor prolyl hydroxylase inhibitors (JESDUVROQ, EVRENZO), which function through hematopoietic mechanisms to suppress porphyrin precursor synthesis. Iron supplementation therapies including FERACCRU and ferumoxytol-based approaches represent an alternative mechanistic strategy. The patient population for porphyria treatment remains small but clinically severe, with significant quality-of-life impact and potential for severe morbidity and mortality during acute attacks. Commercial significance is limited by orphan disease status but supported by high treatment burden and unmet medical need in this population.

Drug Class: Iron supplement; blood and blood-forming organs therapeutic (ATC B03)

Modality: Small molecule

Route of Administration: Intravenous

Active Pharmaceutical Ingredient: Ferumoxytol (FERAHEME)

Mechanism of Action: Not yet disclosed in regulatory documentation

Molecular Target: Not yet disclosed

Related Therapies: Erythropoietin receptor agonists (epoetin alfa, darbepoetin alfa, peginesatide), hypoxia-inducible factor prolyl hydroxylase inhibitors (roxadustat, daprodustat), oral iron supplements

First Approval: Ferumoxytol approved in the United States; European application withdrawn as of 13 April 2015

Patent Status: Not yet disclosed

United States: Ferumoxytol approved under multiple sponsors (AZURITY, SANDOZ) with FDA application numbers ANDA206604, NDA022180, and NDA219868. Status: Approved.

European Union: Ferumoxytol application withdrawn. Previously authorized under MAHs Covis Pharma Europe B.V. and Takeda Pharma A/S with EMA product numbers EMEA/H/C/002215 and EMEA/H/C/005974. Authorization date: 13 April 2015. Status: Application withdrawn.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

The heme arginate program itself (internal code 199/13191) has not achieved regulatory approval; development status remains at Phase 2 completion as of June 2005, with no subsequent milestones or regulatory submissions publicly disclosed.

Development Status: The heme arginate program remains in Phase 2 with completed status as of June 2005, representing a 19+ year gap since the last publicly disclosed milestone. This extended hiatus without reported progression suggests either dormant development status or undisclosed clinical activity. The lack of recent regulatory filings or milestone announcements indicates this program is not actively advancing toward approval.

Competitive Positioning: Ferumoxytol operates within the iron supplementation niche of porphyria treatment, a market segment substantially smaller than the dominant erythropoietin agonist category. The approved ferumoxytol product (FERAHEME) competes in the general iron supplementation market but has not established a dominant position in porphyria-specific treatment. The withdrawn EU application suggests commercial or regulatory challenges in European markets.

Strategic Implications: Ultragenyx UK Limited's continued sponsorship status is not yet disclosed. The absence of partnership announcements or recent development updates suggests limited commercial prioritization. Future catalysts would include: (1) resumption of clinical development with new trial initiation; (2) regulatory submission in any jurisdiction; (3) partnership or licensing announcements; (4) publication of Phase 2 trial results from the three registered studies.

Unmet Need Considerations: While porphyria represents a genuine unmet medical need, the competitive landscape has expanded substantially since 2005 with multiple approved therapeutic classes now available. Any future advancement of heme arginate would require clear differentiation from established erythropoietin agonists and emerging hypoxia-inducible factor inhibitors.